Phoenix Molecular Designs   Report issue

For profit Phase 1
Founded: San Diego CA United States (2012)

Organization Overview

First Clinical Trial
2019
NCT04115306
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Phoenix Molecular Designs

Active Ingredients

Drugs in Phase 1 Trials (1)

pmd-026 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1